HeartBeam (BEAT) Reports Positive Pilot Results for Heart Attack Assessment

What happened

HeartBeam reported positive results from its 132-person ALIGN-ACS pilot, which compared its system with standard 12-lead ECGs for acute coronary syndrome assessment. The study took place at two Serbian cardiology centers. The results are intended to inform a U.S. pivotal study planned for Q1 2027; this use remains investigational and is not FDA-cleared.

Confirmed

Global impact / market context

The pilot offers early evidence for HeartBeam’s system, but it does not establish that the system can reliably assess heart attacks in broader use. If a future pivotal study succeeds and the FDA clears this use, the company could move toward commercial adoption; failure or delay could postpone that opportunity.

Analyst inference

The supplied context describes an early clinical stage: a small, two-center pilot precedes the planned U.S. pivotal study, a larger confirmatory trial. Because heart attack assessment is not FDA-cleared, the results do not yet support treating this use as an authorized product or established source of revenue.

Analyst inference

What to watch

1. Watch whether HeartBeam starts the planned U.S. pivotal study in Q1 2027; the article says the timing is planned, not confirmed. Confirmed
2. Watch for the pivotal study’s design and results, especially whether it shows the system can assess acute coronary syndrome against standard ECGs. Analyst inference
3. Watch whether successful pivotal evidence leads to an FDA submission and clearance; authorization could determine whether HeartBeam can offer this use commercially. Analyst inference

Evidence

• Original source link unavailable